{"nctId":"NCT03737240","briefTitle":"IDegLira HIGH Trial","startDateStruct":{"date":"2019-01-15","type":"ACTUAL"},"conditions":["Diabetes Mellitus"],"count":145,"armGroups":[{"label":"IDegLira","type":"EXPERIMENTAL","interventionNames":["Drug: IDegLira"]},{"label":"Basal-Bolus Insulin","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Insulin Degludec (U-100)","Drug: Insulin Aspart"]}],"interventions":[{"name":"IDegLira","otherNames":["Xultophy 100/3.6","insulin degludec","liraglutide"]},{"name":"Insulin Degludec (U-100)","otherNames":["Tresiba FlexTouch"]},{"name":"Insulin Aspart","otherNames":["NovoLog"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes, diagnosed for ≥ 6 months\n* HBA1c ≥ 9% - 15%\n* Previously treated with oral antidiabetic agents, including metformin, sulfonylurea, repaglinide/nateglinide, pioglitazone, dipeptidyl peptidase-4 (DPP4), inhibitors, SGLT2 inhibitors, (monotherapy + basal insulin) or in combination therapy (2-3 agents), and/or on basal insulin (neutral protamine hagedorn (NPH), detemir or glargine U100) at a total daily dose (TDD) 20-50 units (stable doses of metformin and basal insulin for at least 90 days, defined as up to ±10% variability)\n* Body mass index (BMI) ≤ 45 Kg/m2\n\nExclusion Criteria:\n\n* Subjects with type 1 diabetes or latent autoimmune diabetes of adults (LADA) (positive glutamic acid decarboxylase (GAD-65) antibody and/or ketones)\n* Subjects with a BG \\> 400 mg/dL during the screening visit and laboratory evidence of diabetic ketoacidosis\n* Previous treatment with glucagon-like peptide-1 (GLP-1) agonists (during prior 3 months)\n* Previous treatment with basal-bolus insulin (within prior 3 months)\n* Recurrent severe hypoglycemia or known hypoglycemia unawareness.\n* Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2\n* Patients with acute or chronic pancreatitis, pancreatic cancer\n* Patients with clinically significant hepatic disease (cirrhosis, jaundice, end-stage liver disease) or significantly impaired renal function (GFR \\< 30 ml/min).\n* Treatment with oral or injectable corticosteroid (equivalent or higher than prednisone 5 mg/day), parenteral nutrition and immunosuppressive treatment.\n* Mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study\n* Hypersensitivity to study drugs\n* Participating in another investigational drug trial\n* The receipt of any investigational drug (within 3 months) prior to this trial.\n* Previously randomized in this trial\n* Heart Failure New York Heart Association (NYHA) class 4 or uncontrolled hypertension (blood pressure \\> 180/110 mmHg)\n* Female subjects who are pregnant or breast-feeding at time of enrollment into the study\n* Females of childbearing potential who are not using adequate contraceptive methods (as required by local law or practice)\n* Known or suspected allergy to trial medications (degludec, liraglutide, aspart), excipients, or related products.\n* Subjects could be excluded based on PI's discretion\n* Unable to comply with trial protocol, and/or at investigator discretion\n* Patients receiving treatment for active diabetic retinopathy or with proliferative retinopathy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin A1c (HbA1c)","description":"HbA1c will be compared between study groups. HbA1c measures the average percentage of blood sugar over the past 2 to 3 months and HbA1c can reduce with management of diabetes through diet, exercise, and medication. HbA1c levels below 5.7% are considered normal. Persons with values between 5.7% and 6.4% are considered at high risk of developing diabetes while those with values of 6.5% and above are diagnosed with diabetes. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.18","spread":"2.29"},{"groupId":"OG001","value":"-3.00","spread":"1.79"}]}]}]},{"type":"SECONDARY","title":"Average Fasting Blood Glucose","description":"Mean fasting blood glucose will be compared between study arms. Participants will perform an 8-point, self-monitored blood glucose (SMBG) check by testing their blood sugar at 8 different time points. The measurement taken before breakfast is used to assess fasting blood glucose. For people without diabetes, fasting blood glucose is typically between 70-100 mg/dL while fasting blood glucose for those with diabetes is in the range of 70-130 mg/dL.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"202.37","spread":"63.73"},{"groupId":"OG001","value":"206.53","spread":"58.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"131.94","spread":"45.59"},{"groupId":"OG001","value":"125.18","spread":"29.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.31","spread":"89.55"},{"groupId":"OG001","value":"143.14","spread":"62.81"}]}]}]},{"type":"SECONDARY","title":"Average Daily Blood Glucose","description":"Mean daily blood glucose will be compared between study arms. Participants will perform an 8-point, self-monitored blood glucose (SMBG) check by testing their blood sugar at 8 different time points. Blood glucose levels vary depending on when and what food has been consumed. A blood glucose level taken regardless of timing of meals of greater than 200 mg/dL often indicates diabetes. Blood glucose decreases with improved diabetes management.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"220.81","spread":"64.43"},{"groupId":"OG001","value":"225.18","spread":"65.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.80","spread":"47.72"},{"groupId":"OG001","value":"135.08","spread":"33.51"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"134.59","spread":"36.35"},{"groupId":"OG001","value":"144.25","spread":"40.70"}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c <7.0% and no Hypoglycemia","description":"Percent of study participants experiencing HbA1c \\<7.0% and no hypoglycemia will be compared between groups. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable. Hypoglycemia is defined as a blood glucose level of \\< 70 mg/dL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c <7.0% and no Weight Gain and no Hypoglycemia","description":"Percent of study participants reaching A1c \\< 7% without weight gain and no hypoglycemia will be compared between groups. Weight control is typically important in persons with type 2 diabetes and basal-bolus insulin is associated with weight gain. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable. Hypoglycemia is defined as a blood glucose level of \\< 70 mg/dL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c <7.5% and no Weight Gain and no Hypoglycemia","description":"Percent of study participants reaching A1c \\< 7.5% without weight gain and no hypoglycemia will be compared between groups. Weight control is typically important in persons with type 2 diabetes and basal-bolus insulin is associated with weight gain. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable. Hypoglycemia is defined as a blood glucose level of \\< 70 mg/dL.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"5.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c >10% Achieving HbA1c <7.5%","description":"Percent of study participants with baseline HbA1c \\>10% reaching A1c \\< 7.5% will be compared between study groups. HbA1c measures the average percentage of blood sugar over the past 2 to 3 months and HbA1c can reduce with management of diabetes through diet, exercise, and medication. HbA1c levels below 5.7% are considered normal. Persons with values between 5.7% and 6.4% are considered at high risk of developing diabetes while those with values of 6.5% and above are diagnosed with diabetes. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.8","spread":null},{"groupId":"OG001","value":"37.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c >10% Achieving HbA1c <8.0%","description":"Percent of study participants with baseline HbA1c \\>10% reaching A1c \\< 8.0% will be compared between study groups. HbA1c measures the average percentage of blood sugar over the past 2 to 3 months and HbA1c can reduce with management of diabetes through diet, exercise, and medication. HbA1c levels below 5.7% are considered normal. Persons with values between 5.7% and 6.4% are considered at high risk of developing diabetes while those with values of 6.5% and above are diagnosed with diabetes. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.4","spread":null},{"groupId":"OG001","value":"45.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c >11% Achieving HbA1c <7.5%","description":"Percent of study participants with baseline HbA1c \\>11% reaching A1c \\< 7.5% will be compared between study groups. HbA1c measures the average percentage of blood sugar over the past 2 to 3 months and HbA1c can reduce with management of diabetes through diet, exercise, and medication. HbA1c levels below 5.7% are considered normal. Persons with values between 5.7% and 6.4% are considered at high risk of developing diabetes while those with values of 6.5% and above are diagnosed with diabetes. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.0","spread":null},{"groupId":"OG001","value":"25.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c >11% Achieving HbA1c <8.0%","description":"Percent of study participants with baseline HbA1c \\>11% reaching A1c \\< 8.0% will be compared between study groups. HbA1c measures the average percentage of blood sugar over the past 2 to 3 months and HbA1c can reduce with management of diabetes through diet, exercise, and medication. HbA1c levels below 5.7% are considered normal. Persons with values between 5.7% and 6.4% are considered at high risk of developing diabetes while those with values of 6.5% and above are diagnosed with diabetes. Persons with diabetes aim to get their HbA1c in the range of 7.0 to 7.5% or lower, with below 7.0% being preferable.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.0","spread":null},{"groupId":"OG001","value":"29.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c <7.0% and no Weight Gain","description":"Percent of study participants reaching A1c \\< 7% without weight gain will be compared between groups.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Participants With HbA1c <7.0% and no Hypoglycemia","description":"Percent of study participants reaching A1c \\< 7% without hypoglycemia will be compared between groups. Hypoglycemia is defined as a blood glucose level of \\< 70 mg/dL.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Documented Symptomatic Hypoglycemic Events","description":"Documented symptomatic hypoglycemia is defined as an event with typical symptoms of hypoglycemia accompanied by SMBG \\<70 mg/dL or continuous glucose monitoring (CGM) \\< 54 mg/dL that occurs at any time of the day. Number of participants with documented hypoglycemic events will be compared between study groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"26","spread":null}]}]}]},{"type":"SECONDARY","title":"Asymptomatic Hypoglycemic Events","description":"Asymptomatic hypoglycemia is defined as no typical symptoms reported by the study participant but detected by SMBG \\<70 mg/dL or continuous glucose monitoring (CGM) \\< 54 mg/dL. Incidence of asymptomatic hypoglycemic events will be compared between study groups.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Number of Participants With Severe Hypoglycemic Events","description":"Severe hypoglycemia is defined as severe cognitive impairment requiring assistance from another person. Number of participants with severe hypoglycemic events will be compared between study groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Nocturnal Symptomatic Hypoglycemic Events","description":"Nocturnal symptomatic hypoglycemia is defined as an event with typical symptoms of hypoglycemia accompanied by SMBG \\<70 mg/dL or continuous glucose monitoring (CGM) \\< 54 mg/dL that occurs between midnight and 5:59 am. Incidence of nocturnal symptomatic hypoglycemic events will be compared between study groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.15","spread":"1.30"},{"groupId":"OG001","value":"0.16","spread":"0.65"}]}]}]},{"type":"SECONDARY","title":"Nocturnal Asymptomatic Hypoglycemic Events","description":"Nocturnal asymptomatic hypoglycemia is defined as SMBG \\<70 mg/dL or continuous glucose monitoring (CGM) \\< 54 mg/dL between midnight and 5:59 am. Incidence of nocturnal asymptomatic hypoglycemic events will be compared between study groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.81","spread":"7.85"},{"groupId":"OG001","value":"3.45","spread":"6.30"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time With Interstitial Glucose <70 mg/dL","description":"Percentage of time with a interstitial glucose level below 70 mg/dL as obtained by CGM will be compared between study groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.67","spread":"7.08"},{"groupId":"OG001","value":"1.23","spread":"2.82"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time With Interstitial Glucose <54 mg/dL","description":"Percentage of time with a interstitial glucose level below \\<54 mg/dL as obtained by CGM will be compared between study groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.31","spread":"1.22"},{"groupId":"OG001","value":"0.72","spread":"2.48"}]}]}]},{"type":"SECONDARY","title":"Percentage of Time With Interstitial Glucose Between 70 and 180 mg/dL","description":"Percentage of time with interstitial glucose in the range of 70-180 mg/dL as measured by CGM will be compared between study groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.39","spread":"30.69"},{"groupId":"OG001","value":"31.17","spread":"29.00"}]}]}]},{"type":"SECONDARY","title":"Glycemic Variability","description":"Glycemic variability will be assessed with continuous glucose monitoring (CGM). It will be calculated using CGM and Standard Deviation.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":"14.6"},{"groupId":"OG001","value":"51.6","spread":"13.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.8","spread":"14.8"},{"groupId":"OG001","value":"47.1","spread":"15.4"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.6","spread":"14.8"},{"groupId":"OG001","value":"48.4","spread":"16.2"}]}]}]},{"type":"SECONDARY","title":"Diabetes Treatment Satisfaction Questionnaire - Status (DTSQs) Score","description":"Treatment satisfaction will be assessed with the DTSQs. The DTSQs contains eight items scored on a seven-point scale where 0 = very dissatisfied and 6 = very satisfied. The satisfaction score is obtained by summing responses to yield a total score between 0 to 48. Higher scores indicate higher satisfaction with diabetes treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26.00","spread":"8.06"},{"groupId":"OG001","value":"29.07","spread":"6.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.15","spread":"3.93"},{"groupId":"OG001","value":"33.94","spread":"2.58"}]}]}]},{"type":"SECONDARY","title":"Diabetes Treatment Satisfaction Questionnaire - Change (DTSQc) Score","description":"Satisfaction with the study treatment will be assessed with items 1, 4, 5, 6, 7, and 8 the DTSQc. Items are rated on a scale of -3 (much less satisfied compared to prior treatment) to 3 (much more satisfied compared to prior treatment). Total scores for these three items range from -18 to +18 with higher scores indicating greater satisfaction with the study treatment compared to their prior treatment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.55","spread":"4.68"},{"groupId":"OG001","value":"15.77","spread":"3.13"}]}]}]},{"type":"SECONDARY","title":"Treatment-Related Impact Measures for Diabetes (TRIM-D) Survey Score","description":"Satisfaction with the study treatment will be assessed with the TRIM-D survey. TRIM-D includes 28 items that are scored on a scale from 1 to 5. Total scores are transformed to a scale of 0 to 100 where higher scores indicate increased satisfaction.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.94","spread":"2.29"},{"groupId":"OG001","value":"15.37","spread":"2.61"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.82","spread":"1.70"},{"groupId":"OG001","value":"15.29","spread":"2.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.19","spread":"1.88"},{"groupId":"OG001","value":"15.29","spread":"1.88"}]}]}]},{"type":"SECONDARY","title":"Number of Emergency Room (ER) Visits","description":"The number of emergency room visits occurring during the treatment period will be compared between study groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Hospital Readmissions","description":"The number of hospital readmissions occurring during the treatment period will be compared between study groups.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Daily Insulin Dose","description":"The total insulin dose measured in units per day will be compared between study groups.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24.56","spread":"7.76"},{"groupId":"OG001","value":"46.05","spread":"20.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.74","spread":"17.53"},{"groupId":"OG001","value":"75.65","spread":"43.43"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":14,"n":72},"commonTop":["Nausea","Abdominal Pain","Diarrhea","Vomiting"]}}}